<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Gershenson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rochelle L Garcia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4402092"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovarian sex cord-stromal tumors (SCSTs  (<a class="graphic graphic_table graphicRef77703" href="/d/graphic/77703.html" rel="external">table 1</a>)) are a group of benign and malignant neoplasms that develop from the sex cord (eg, Sertoli cell tumor, granulosa cell tumor) or stromal cells (eg, fibroma, thecoma, Leydig cell tumor) or both (eg, Sertoli-Leydig cell tumor). Some ovarian SCSTs produce steroid hormones, particularly androgens or estrogens, and thus may present with signs of virilization or estrogen excess  (<a class="graphic graphic_table graphicRef55817" href="/d/graphic/55817.html" rel="external">table 2</a>) [<a href="#rid1">1,2</a>]. </p><p>Ovarian SCSTs are less common than tumors of epithelial cell and germ cell origin. Benign ovarian SCSTs account for &lt;4 percent of ovarian benign neoplasms, and malignant ovarian SCSTs account for &lt;8 percent of ovarian malignant neoplasms. In contrast to the more common epithelial ovarian malignant neoplasms, most patients with malignant SCSTs are diagnosed with early-stage disease [<a href="#rid3">3</a>]. Histology is generally low grade, lymph node metastases are rare, and prognosis is good [<a href="#rid4">4-6</a>]. However, some neoplasms are aggressive and have a lethal outcome.</p><p>This topic will discuss the epidemiology, clinical features, and diagnosis of ovarian SCSTs. Many patients with SCSTs present with an adnexal mass; the initial approach to the patient who presents with an adnexal mass is discussed separately (see  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>). Management of SCSTs is also reviewed separately. (See  <a class="medical medical_review" href="/d/html/126385.html" rel="external">"Sex cord-stromal tumors of the ovary: Management in adults"</a>.) </p><p class="headingAnchor" id="H727542"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the Surveillance, Epidemiology, and End Results (SEER) United States national cancer database, the incidence of SCSTs was 0.2 per 100,000 females [<a href="#rid3">3</a>]. The average age at diagnosis was 50 years (compared with 61 years for epithelial ovarian cancer); 12 percent of patients were younger than age 30, and 57 percent were between ages 30 and 59. The incidence was higher in Black patients than in White patients (0.44 versus 0.18 per 100,000). </p><p>In a separate retrospective study, older age at last birth (≥40 years) and shorter time since last birth (&lt;10 years) were associated with a reduction in risk of SCSTs [<a href="#rid7">7</a>].</p><p>Malignant SCSTs account for less than 8 percent of ovarian malignant neoplasms. In contrast to ovarian carcinomas, most SCSTs have no association with the <em>BRCA</em> germline mutations or a genetic predisposition to breast cancer. An exception is granulosa cell tumors, which appear to be more common in patients who have a family history of breast or ovarian cancer [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H2646226737"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Ovarian SCSTs arise from the dividing cells that would typically give rise to specialized gonadal stroma surrounding the oocytes, including granulosa cells, theca cells, Sertoli cells, Leydig cells, and fibroblasts  (<a class="graphic graphic_figure graphicRef72286" href="/d/graphic/72286.html" rel="external">figure 1</a>). In comparison, the two major other types of ovarian neoplasms originate from germ cells or from the dividing cell population that gives rise to müllerian epithelium, ovarian surface epithelium, or fallopian tube epithelium.</p><p>Morphologically, SCSTs display at least some areas with unequivocal gonadal stromal differentiation, such as granulosa, theca, Sertoli, or Leydig cell differentiation. They may display indifferent morphologic features, such as fibroblastic differentiation, and may contain areas of other types of stromal differentiation (eg, cartilage or skeletal muscle) or areas of epithelial differentiation ("heterologous elements"). This may happen because the dividing cell population from which these neoplasms arise may still have capacity for various lines of differentiation. Most consist of ovarian cell types, but testicular (Sertoli cell) and mixed ovarian and testicular (gynandroblastoma) cell types can occur.</p><p class="headingAnchor" id="H8419842"><span class="h1">CLINICAL PRESENTATION AND DIAGNOSTIC CONSIDERATIONS</span></p><p class="headingAnchor" id="H3814116551"><span class="h2">Nonspecific signs and symptoms</span><span class="headingEndMark"> — </span>Patients with SCSTs generally present in the same way as patients with epithelial or germ cell ovarian neoplasms: because of abdominal or pelvic symptoms from the mass or as an incidental finding of adnexal mass on examination or imaging. Further details on diagnostic considerations in patients presenting with an adnexal mass are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis"</a>.)</p><p>Some SCSTs can have characteristic clinical presentations, as described below.</p><p class="headingAnchor" id="H1606231540"><span class="h2">Estrogenic and androgenic effects</span><span class="headingEndMark"> — </span>Some SCSTs secrete androgens, estrogens, or other steroid hormones that can cause clinical manifestations related to the hormonal profile  (<a class="graphic graphic_table graphicRef55817" href="/d/graphic/55817.html" rel="external">table 2</a>). </p><p>Signs of estrogen excess include abnormal uterine bleeding, endometrial neoplasm, or, in a child, precocious puberty. The differential diagnosis in patients who present with both an adnexal mass and abnormal uterine bleeding includes SCSTs as well as an ovarian metastasis from a primary uterine cancer, an endometrial metastasis from a primary ovarian malignant neoplasm, and separate primary ovarian and endometrial carcinomas. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a> and  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p>Signs of androgen excess (virilization) include hirsutism, acne, alopecia (male pattern baldness), menstrual abnormalities (oligomenorrhea, amenorrhea), clitoromegaly, and deepening voice [<a href="#rid1">1,9</a>]. (See  <a class="medical medical_review" href="/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a>.)</p><p class="headingAnchor" id="H1402785282"><span class="h2">Ascites with or without other abdominal symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ovarian fibroma and ascites and/or pleural effusion may have Meigs syndrome [<a href="#rid10">10</a>]. Fluid accumulation is probably related to substances like vascular endothelial growth factor that raise capillary permeability [<a href="#rid11">11,12</a>]. Removal of the neoplasm results in elimination of ascites and pleural effusion [<a href="#rid13">13</a>]. Several cases of Meigs syndrome have been reported in association with elevated serum cancer antigen 125 (CA 125) levels [<a href="#rid14">14</a>]. Thus, neither ascites nor pleural effusion, nor an elevated CA 125, is necessarily indicative of an advanced epithelial ovarian carcinoma in a patient with a pelvic mass. (See <a class="local">'Fibroma'</a> below.)</p><p></p><p class="bulletIndent1">Pseudo-Meigs syndrome (a clinical syndrome of pleural effusion, ascites, and an ovarian mass that is not a fibroma or fibroma-like mass/tumor) has been reported from a number of sources, such as leiomyomas, struma ovarii, mucinous cystadenoma, teratoma, and malignancies that are metastatic to the ovary (particularly colorectal cancer) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with luteinized thecoma associated with sclerosing peritonitis commonly have massive ascites, which cause acute abdominal distension and pain. Some patients may have bowel obstruction. (See <a class="local">'Luteinized thecoma associated with sclerosing peritonitis'</a> below.)</p><p></p><p class="headingAnchor" id="H3371938862"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>An SCST is typically suspected in those patients who present with both an adnexal mass and endocrine effects since the vast majority of adnexal masses do not cause these effects. In such instances, the work-up typically includes a combination of laboratory tests (eg, total testosterone if virilization is present, estradiol if signs of excess estrogen, and possibly SCST tumor markers such as inhibin A and B and alpha-fetoprotein  (<a class="graphic graphic_table graphicRef55817" href="/d/graphic/55817.html" rel="external">table 2</a>)). As with other adnexal masses, imaging studies are also used, as discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Role of tumor markers and multimodal tests'</a> and  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Role of additional imaging'</a>.)</p><p>Endometrial sampling should be performed in premenopausal patients with an adnexal mass and abnormal uterine bleeding and in postmenopausal patients with a thickened (&gt;4 to 5 mm) endometrial stripe on transvaginal ultrasound examination since these signs/symptoms can be due to excess estrogen production and affect management. For example, endometrial sampling will detect endometrial hyperplasia/intraepithelial neoplasia in 25 to 50 percent of patients with granulosa cell tumors and carcinoma in 5 to 10 percent [<a href="#rid16">16-18</a>]. In patients with thecoma, carcinoma is present in approximately 20 to 25 percent of patients, and another 15 percent have a precursor lesion. (See  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease"</a>.)</p><p>In all patients with an adnexal mass, surgery is performed to resect and determine the histology of an ovarian mass if ultrasound findings suggest the mass has some reasonable chance of being malignant  (<a class="graphic graphic_table graphicRef79259" href="/d/graphic/79259.html" rel="external">table 3</a>). Surgery to resect the mass is also performed if there are other risks associated with the mass (eg, torsion) or the mass is causing symptoms. Patients with SCSTs generally meet one or more of these criteria. When a malignant neoplasm is suspected, the entire ovary must be removed. Biopsy of the ovary or cystectomy results in potential spread of neoplastic cells and upstaging that impacts prognosis.</p><p class="headingAnchor" id="H922378768"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of ovarian SCST is a histologic diagnosis. While the diagnosis may be suspected preoperatively based on the presence of an adnexal mass combined with signs of estrogen or androgen excess or elevated levels of serum tumor markers, the specific histologic type and risk of malignancy require examination of a surgical specimen. In addition, many expert gynecologic pathologists will not provide a definite diagnosis of SCSTs based upon intraoperative frozen section examination because they are rare and can be mimicked by epithelial ovarian neoplasms (particularly endometrioid neoplasm) or vice versa. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>.)</p><p>Genomic analysis of SCSTs does not have a clear clinical role in diagnosis or targeted treatment of these tumors but is under investigation [<a href="#rid19">19,20</a>].</p><p class="headingAnchor" id="H100155420"><span class="h1">HISTOPATHOLOGY AND CLINICAL BEHAVIOR</span></p><p class="headingAnchor" id="H764891564"><span class="h2">General features</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) classification of ovarian SCSTs and other ovarian neoplasms is shown in the table  (<a class="graphic graphic_table graphicRef77703" href="/d/graphic/77703.html" rel="external">table 1</a>) [<a href="#rid21">21,22</a>]. Selected SCSTs, particularly those that may display malignant behavior, are discussed in the sections below and in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p>The pattern of spread and likelihood of distant metastases vary greatly by histologic subtype, but nodal metastases are rare [<a href="#rid4">4,5</a>]. As an example, in a retrospective series of 87 patients with mostly granulosa cell or Sertoli-Leydig cell neoplasms, there were no patients with positive lymph nodes [<a href="#rid6">6</a>]. Among patients with stage III and IV disease, regional spread was abdominal (eg, diaphragm and omentum).</p><p>In contrast to the more common ovarian carcinomas, malignant SCSTs are often diagnosed at an early stage, and histology is generally low grade; however, some tumors are aggressive and have a lethal outcome. A study using Surveillance, Epidemiology, and End Results (SEER) United States national cancer database data reported the following distribution of stage at diagnosis: confined to the ovary (57 percent), spread to surrounding organs or tissues (15 percent), and distant metastases (22 percent) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4119008756"><span class="h2">Pure stromal tumors</span></p><p class="headingAnchor" id="H2136367992"><span class="h3">Fibroma</span><span class="headingEndMark"> — </span>Fibromas are the most common of the benign SCSTs and account for 4 percent of all ovarian neoplasms. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – Fibromas are made almost entirely of fibroblasts. Cellular fibromas are a type of fibroma characterized by mildly increased cellular density, mild nuclear atypia, and an average of three or fewer mitotic figures per 10 high power fields (HPF). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genomics</strong> – Ovarian fibromas associated with basal cell cancers are called nevoid basal cell carcinoma syndrome or Gorlin syndrome. Whether the inherited germline abnormality responsible for Gorlin syndrome (a mutation in the patched or <em>PTCH1</em> gene on chromosome 9) is related to the development of ovarian fibromas as well is unclear [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Fibromas are benign and have neither estrogenic nor androgenic effects. Approximately 10 percent of fibromatous tumors of the ovary demonstrate increased cellularity and varying degrees of mitotic activity [<a href="#rid24">24,25</a>]. Cellular tumors are classified as cellular fibromas; those with mitotic activity are considered tumors of low malignant potential.</p><p></p><p class="headingAnchor" id="H1660193870"><span class="h3">Thecoma</span><span class="headingEndMark"> — </span>Thecomas are rare. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – Thecomas are composed of theca cells but may also contain granulosa cell components; such tumors are designated granulosa-theca cell tumors [<a href="#rid26">26</a>]. If granulosa cells predominate, then they are considered granulosa cell tumors. (See <a class="local">'Granulosa cell tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Pure thecomas are benign and commonly display estrogenic effects. Malignant behavior is rare. (See <a class="local">'Other'</a> below and <a class="local">'Granulosa cell tumors'</a> below.)</p><p></p><p class="headingAnchor" id="H808981443"><span class="h3">Fibrothecoma</span><span class="headingEndMark"> — </span>The term "fibrothecoma" is used by some experts to refer to a rare neoplasm with features that are intermediate between a fibroma and a thecoma, but fibrothecoma is not part of the WHO classification of tumors of the ovary [<a href="#rid27">27</a>]. There is no universal agreement on which neoplasms should be classified as a fibrothecoma rather than either a fibroma or a thecoma; however, many neoplasms have mixtures of these cell types. Most of these tumors are benign [<a href="#rid28">28,29</a>]. The risk of malignant neoplasm is difficult to predict due to inconsistent classification and the paucity of data regarding these neoplasms. Hormonal activity depends upon the extent to which they resemble fibromas (lipid poor, hormonally inert) or thecomas (lipid containing, hormonally [estrogen] active) [<a href="#rid27">27,30</a>]. Patients with a significant amount of hormonally active thecoma elements are at risk for endometrial neoplasia, similar to pure thecomas. On ultrasound, the tumors tend to be large and solid tumors, and may have areas of edema and cystic degeneration.</p><p class="headingAnchor" id="H2529445511"><span class="h3">Luteinized thecoma associated with sclerosing peritonitis</span><span class="headingEndMark"> — </span>Luteinized thecoma associated with sclerosing peritonitis is rare. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – A large tumor may replace the entire ovary, but smaller lesions may circumferentially involve the ovarian cortex with sparing of the medullary region of the ovary. Other microscopic features may include a high mitotic count, prominent cellular lobules, hemorrhage, edema, and cytologically bland spindle-shaped cells. There is no pathognomonic immunohistochemical staining pattern. Luteinized cells may be positive for alpha-inhibin, calretinin, and CD56, and spindled cells may be alpha-smooth muscle actin positive or desmin positive [<a href="#rid31">31</a>].<strong> </strong>A proportion of tumors may be estrogen receptor or progesterone receptor positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Luteinized thecoma associated with sclerosing peritonitis is a benign tumor. Hormonal manifestations are usually absent, but one patient with an elevated testosterone level and one patient with menorrhagia have been reported [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">At surgery, there is significant thickening of the peritoneum (sclerosing peritonitis) with involvement of the omentum, peritoneal surfaces, and small intestine. The sclerosing peritonitis may cause significant morbidity, including severe adhesions, intestinal obstruction, fistulas, and death [<a href="#rid31">31,32</a>]. The cause of the sclerosing peritonitis is unknown, but the most popular theories involve either some type of inciting agent that causes both the ovarian pathology and the peritoneal fibrosis, or the secretion of some type of substance by the ovaries that results in the associated peritoneal fibrosis. There have been reports of an association between this entity and antiseizure medications, beta-adrenergic blocking agents, or peritoneal dialysis [<a href="#rid33">33-35</a>].</p><p></p><p class="headingAnchor" id="H2137527496"><span class="h3">Fibrosarcoma</span><span class="headingEndMark"> — </span>Fibrosarcomas are extremely rare. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – Fibrosarcomas have four or more mitotic figures per 10 HPF plus marked cellular density and nuclear atypia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Fibrosarcomas are very rare malignant ovarian sarcomas. Aggressiveness correlates with the number of mitoses and the degree of anaplasia. Hormonal effects are generally absent.</p><p></p><p class="headingAnchor" id="H248012279"><span class="h2">Pure sex cord tumors</span></p><p class="headingAnchor" id="H1580947940"><span class="h3">Granulosa cell tumors</span><span class="headingEndMark"> — </span>Granulosa cell tumors are the most common type of potentially malignant ovarian SCST; they comprise 2 to 5 percent of all ovarian malignant neoplasms and 90 percent of malignant SCSTs [<a href="#rid36">36</a>]. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – There are two subtypes: adult (95 percent of cases) and juvenile (5 percent of cases). Granulosa cells of the adult subtype appear round to oblong, pale, with scant cytoplasm, and classic "coffee-bean" grooved nuclei; atypia and mitoses are typically not frequent but do occur  (<a class="graphic graphic_picture graphicRef79902" href="/d/graphic/79902.html" rel="external">picture 1</a>). The cells may arrange themselves in small clusters or rosettes around a central cavity. These arrangements, which are termed "Call-Exner bodies," resemble primordial follicles and, when diffusely present, constitute a microfollicular pattern [<a href="#rid37">37</a>]. Lack of Call-Exner bodies is not infrequent.</p><p></p><p class="bulletIndent1">Juvenile subtype has a macrofollicular or cystic pattern and is composed of immature granulosa cells with frequent mitoses; Call-Exner bodies and coffee-bean grooved nuclei are infrequent.</p><p></p><p class="bulletIndent1">Theca cells, which are luteinized cells within the stroma, are present in approximately 70 percent of cases. Theca cells produce androstenedione, a weak androgen, and granulosa cells convert the androstenedione to estradiol. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genomics</strong> – <em>FOXL2</em> encodes a transcription factor that is expressed as a nuclear protein and is critically important in the development of granulosa cells [<a href="#rid38">38,39</a>]. Somatic mutations in <em>FOXL2</em> have been identified in 97 percent of adult subtype granulosa cell tumors [<a href="#rid38">38,40</a>]. By contrast, the mutation was identified in only 1 of 10 juvenile subtype granulosa cell tumors and 3 of 14 thecomas (21 percent), while it was absent in SCSTs of other types and in other ovarian neoplasms. In a retrospective study including 423 adult granulosa cell tumor profiles, the most common mutations identified included <em>TERT </em>(54 percent), <em>KMT2D</em> (17 percent), and <em>TP53</em> (8 percent) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Most granulosa cell tumors have an indolent growth pattern. Estrogen effects are common; androgenic effects are also possible. The prognosis depends upon the stage of disease at diagnosis and the presence of residual disease after surgery  (<a class="graphic graphic_table graphicRef67595" href="/d/graphic/67595.html" rel="external">table 5</a>) [<a href="#rid17">17,26,42-45</a>]. Outcomes tend to be less favorable in the presence of a large tumor size (10 to 15 cm) or (in many but not all series [<a href="#rid46">46</a>]) tumor rupture [<a href="#rid43">43,47-50</a>]. These tumors have metastatic potential and a tendency for late relapse. In one report of 37 patients with stage I disease, survival rates at 5, 10, and 20 years were 94, 82, and 62 percent, respectively [<a href="#rid51">51</a>]. The median time to relapse is approximately four to six years after initial diagnosis; however, late recurrences have been reported after as many as 40 years [<a href="#rid12">12,43,47,51-53</a>]. </p><p></p><p class="bulletIndent1">A number of histologic features have also been examined for their prognostic significance. In adult neoplasms, cellular atypia, high mitotic index (4 to 10 mitoses per 10 HPF), and the absence of Call-Exner bodies are the only significant histologic predictors of early recurrence [<a href="#rid43">43,46,52</a>]. Abnormal karyotype, p53 overexpression, and ploidy do not appear to be of prognostic value [<a href="#rid54">54,55</a>].</p><p></p><p class="headingAnchor" id="H3749433854"><span class="h3">Sertoli cell</span><span class="headingEndMark"> — </span>Sertoli cell tumors are rare. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – Closely packed hollow or solid tubules with no or rare Leydig cells [<a href="#rid56">56</a>]. The tumor cells forming the tubules have abundant eosinophilic or vacuolated cytoplasm. Some tumors have marked atypia and increased mitotic index (&gt;5 per 10 HPF), which correlates with more aggressive behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genomics</strong> – Patients with Peutz-Jeghers syndrome (PJS) appear to be predisposed to Sertoli cell tumors, although sex cord tumors with annular tubules (SCTATs) are more common. In one series of 54 patients with Sertoli cell tumors, 6 had PJS [<a href="#rid57">57</a>]; others have reported a similar association [<a href="#rid58">58-60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Most Sertoli cell tumors are stage I at diagnosis and clinically benign, but higher stage cases have been reported, and approximately 11 percent of stage I tumors have atypical features (size &gt;5 cm, &gt;5 mitoses per 10 HPF, nuclear atypia, or necrosis) with the potential for malignant behavior [<a href="#rid36">36,57</a>].</p><p></p><p class="headingAnchor" id="H693579748"><span class="h3">Sex cord tumors with annular tubules</span><span class="headingEndMark"> — </span>SCTATs are rare. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – SCTATs are characterized by simple and complex annular (ring-shaped) tubules. They have been described as having morphologic features intermediate between those of Sertoli cell and granulosa cell tumors [<a href="#rid61">61</a>]. It has been suggested that they arise from granulosa cells but grow in a pattern more characteristic of Sertoli cells [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genomics </strong>– Approximately 30 percent of SCTATs are associated with PJS, an autosomal dominant disorder [<a href="#rid63">63,64</a>]. PJS is caused by germline-inactivating variants of <em>STK11</em>, a tumor suppressor gene. Loss of heterozygosity is also identified in SCTATs associated with PJS. (See  <a class="medical medical_review" href="/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Epidemiology and genetics'</a>.)</p><p></p><p class="bulletIndent1">Sporadic type (most common) SCTATs have no evidence of somatic <em>STK11</em> mutations and only rare cases of loss of heterozygosity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Almost all patients have signs/symptoms of excess estrogen.</p><p></p><p class="bulletIndent1">PJS-associated SCTATs are usually benign and do not have malignant potential, with rare exceptions (three case reports of malignant transformation in SCTATs associated with PJS [<a href="#rid65">65-67</a>]). However, patients with PJS are at risk for a variety of other gynecologic and nongynecologic malignancies. (See  <a class="medical medical_review" href="/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Cancer risk'</a> and  <a class="medical medical_review" href="/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Cancer screening'</a>.)</p><p></p><p class="bulletIndent1">Patients with sporadic SCTATs have a 20 percent incidence of metastasis at initial surgery [<a href="#rid64">64,68-70</a>].</p><p></p><p class="headingAnchor" id="H1011410969"><span class="h2">Mixed sex cord-stromal tumors</span></p><p class="headingAnchor" id="H13582575"><span class="h3">Sertoli-Leydig cell tumors</span><span class="headingEndMark"> — </span>Sertoli-Leydig cell tumors are rare. There are four subtypes: well differentiated, moderately differentiated (formerly intermediate differentiation), poorly differentiated, and retiform. The moderately differentiated, poorly differentiated, and retiform types may have heterologous elements. Clinical characteristics are described in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic appearance</strong> – Well differentiated neoplasms are composed of hollow or solid tubules surrounded by a fibrous stroma  (<a class="graphic graphic_picture graphicRef65893" href="/d/graphic/65893.html" rel="external">picture 2</a>); Sertoli cells line the tubules, and Leydig cells are observed within the stroma.</p><p></p><p class="bulletIndent1">In moderately or poorly differentiated neoplasms, dense cellular areas with increasing numbers of mitoses are seen.</p><p></p><p class="bulletIndent1">The retiform pattern is characterized by a network of irregularly branching, narrow, slit-like tubules and cysts with papillary or polypoid projections resembling the rete testis and rete ovarii. This pattern has been associated with hepatocytic differentiation and increased serum levels of alpha-fetoprotein [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Mucinous epithelium is the most common element in heterologous tumors, but rhabdomyoblasts, cartilage, hepatoid elements, carcinoid tumor, and neuroblastoma have also been observed [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genomics</strong> – Two gene mutations associated with Sertoli-Leydig cell tumors have been reported and can help with diagnosis since SCSTs can exhibit unusual or overlapping features and may mimic non-SCSTs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>FOXL2</em> is a somatic missense point mutation expressed as a nuclear protein mainly in the adult ovary. In one study, <em>FOXL2</em> immunostaining was a relatively sensitive (80 percent) and highly specific (99 percent) marker for SCSTs of the ovary overall, with more modest sensitivity for Sertoli-Leydig cell tumors (50 percent) because of poor immunoexpression in the retiform and poorly differentiated subtypes [<a href="#rid19">19</a>]. Molecular testing for the<em> FOXL2</em> (402C-G) mutation was less sensitive than immunostaining, detecting 3 of 40 cases (7.5 percent) of Sertoli-Leydig cell tumors in the same study. Together with alpha-inhibin and calretinin, <em>FOXL2 </em>can be used as an immunomarker panel to aid in distinguishing SCSTs from non-SCSTs when morphology alone is equivocal. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>DICER1 </em>is an endoribonuclease in the RNase III family that is essential for processing microRNAs. Somatic<em> DICER1 </em>mutations are common in Sertoli-Leydig cell tumors. In one report,<em> DICER1 </em>mutations in the RNase IIIb domain were found in 26 of 43 (60 percent) Sertoli-Leydig cell tumors, including 4 tumors with additional germline<em> DICER1 </em>mutations [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent2"><em>DICER1</em> germline mutations have also been associated with pleuropulmonary blastoma (PPB), a childhood cancer. In a series of 325 children with PPB, 3 children and 3 of their family members had Sertoli-Leydig cell tumors, suggesting that Sertoli-Leydig cell tumors may be a manifestation of the familial PPB syndrome and may be the initial presentation of<em> DICER1</em> mutations within a family [<a href="#rid74">74</a>]. </p><p></p><p class="bulletIndent2">Other clinical conditions that have been associated with germline <em>DICER1 </em>mutations include other nonepithelial ovarian cancers, lung cysts, cystic nephroma, thyroid nodular hyperplasia and differentiated carcinomas, and sarcoma botryoides [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavior</strong> – Sertoli-Leydig cell tumors are typically benign, but malignant behavior is more likely with higher grade disease. Androgenic effects are common; estrogenic effects are less common. </p><p></p><p class="bulletIndent1">In a series of 207 patients with Sertoli-Leydig cell tumors, the level of differentiation was well, intermediate, and poor in 11, 54, and 13 percent, respectively, and 22 percent contained heterologous elements [<a href="#rid76">76</a>]. With prolonged follow-up, the tumor was clinically malignant (ie, it recurred and/or metastasized) in 18 percent of patients. All of the well differentiated tumors had benign behavior, while malignant behavior occurred in 11 percent of those with intermediate differentiation, 59 percent of poorly differentiated tumors, and 19 percent of those with heterologous elements.</p><p></p><p class="headingAnchor" id="H1573313432"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>Gynandroblastoma is no longer considered an entity in the 2014 WHO classification system. Nevertheless, senior expert gynecologic pathologists still believe that gynandroblastoma exists but is exceedingly rare. </p><p></p><p class="bulletIndent1">Patient age at diagnosis ranges from 16 to 65 years (average 30 years) [<a href="#rid77">77</a>]. These tumors can be associated with androgen and (less commonly) estrogen production.</p><p></p><p class="bulletIndent1">The current classification system divides this category into:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pure stromal tumors</p><p class="bulletIndent2"><span class="glyph">•</span>Pure sex cord tumors</p><p class="bulletIndent2"><span class="glyph">•</span>Mixed SCSTs  (<a class="graphic graphic_table graphicRef77703" href="/d/graphic/77703.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1">Gynandroblastomas are usually benign, small neoplasms with Sertoli-Leydig and granulosa cell differentiation [<a href="#rid78">78</a>]. The diagnosis should be reserved for neoplasms containing at least 10 percent of the minor component (Sertoli-Leydig or granulosa).</p><p></p><p class="headingAnchor" id="H1924534492"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119533.html" rel="external">"Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H26118473"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83539.html" rel="external">"Patient education: Sertoli-Leydig cell tumor (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4402156"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian sex cord-stromal tumors (SCSTs)  (<a class="graphic graphic_table graphicRef77703" href="/d/graphic/77703.html" rel="external">table 1</a>) are a rare group of benign and malignant neoplasms. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SCSTs generally present similarly to patients with epithelial or germ cell ovarian neoplasms: because of abdominal or pelvic symptoms from the mass or as an incidental finding of adnexal mass on examination or imaging. Because some SCSTs produce androgens and/or estrogen, patients with these histologic types may present with signs of virilization or estrogen excess. (See <a class="local">'Clinical presentation and diagnostic considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ovarian fibromas or luteinized thecoma associated with sclerosing peritonitis may present with ascites. Sclerosing peritonitis can also cause bowel obstruction. (See <a class="local">'Ascites with or without other abdominal symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast to the more common epithelial ovarian cancer, malignant SCSTs are often diagnosed at an early stage, histology is generally low grade, lymph node metastases are rare, and prognosis is good. However, some tumors are aggressive and have a lethal outcome (eg, fibrosarcoma). (See <a class="local">'General features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an SCST is suspected because of the combination of an adnexal mass and endocrine effects, the diagnostic work-up includes laboratory tests (eg, testosterone, estradiol, tumor markers) and imaging studies. Endometrial sampling should be performed in premenopausal patients with an adnexal mass and abnormal uterine bleeding and in postmenopausal patients with a thickened (&gt;4 to 5 mm) endometrial stripe on transvaginal ultrasound examination since these signs/symptoms can be due to excess estrogen production and affect management. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all patients with an adnexal mass, surgery is performed to resect and determine the histology of an ovarian mass if ultrasound findings suggest the mass has some reasonable chance of being malignant  (<a class="graphic graphic_table graphicRef79259" href="/d/graphic/79259.html" rel="external">table 3</a>). Surgery to resect the mass is also performed if there are other risks associated with the mass (eg, torsion) or the mass is causing symptoms. Patients with SCSTs generally meet one or more of these criteria. (See <a class="local">'Diagnostic evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of ovarian SCST is a histologic diagnosis. The World Health Organization classification of ovarian SCSTs and other ovarian neoplasms is shown in the table  (<a class="graphic graphic_table graphicRef77703" href="/d/graphic/77703.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibromas are the most common of the benign SCSTs. Granulosa cell tumors are the most common type of potentially malignant ovarian SCST. Comparative characteristics of several types of SCSTs are shown in the table  (<a class="graphic graphic_table graphicRef126482" href="/d/graphic/126482.html" rel="external">table 4</a>). (See <a class="local">'Histopathology and clinical behavior'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Varras M, Vasilakaki T, Skafida E, Akrivis C. Clinical, ultrasonographic, computed tomography and histopathological manifestations of ovarian steroid cell tumour, not otherwise specified: our experience of a rare case with female virilisation and review of the literature. Gynecol Endocrinol 2011; 27:412.</a></li><li><a class="nounderline abstract_t">Busquets M, Gonzalez-Bosquet E, Muchart J, et al. Granulosa cell tumor and endometrial cancer: a case report and review of the literature. Eur J Gynaecol Oncol 2010; 31:575.</a></li><li><a class="nounderline abstract_t">Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97:519.</a></li><li><a class="nounderline abstract_t">Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86.</a></li><li><a class="nounderline abstract_t">Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol 2006; 103:31.</a></li><li><a class="nounderline abstract_t">Thrall MM, Paley P, Pizer E, et al. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol 2011; 122:242.</a></li><li><a class="nounderline abstract_t">Sköld C, Bjørge T, Ekbom A, et al. Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study. Br J Cancer 2020; 123:161.</a></li><li><a class="nounderline abstract_t">Boyce EA, Costaggini I, Vitonis A, et al. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol 2009; 115:221.</a></li><li><a class="nounderline abstract_t">Outwater EK, Wagner BJ, Mannion C, et al. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics 1998; 18:1523.</a></li><li><a class="nounderline abstract_t">Brun JL. Demons syndrome revisited: a review of the literature. Gynecol Oncol 2007; 105:796.</a></li><li><a class="nounderline abstract_t">Boggess JF, Soules MR, Goff BA, et al. Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol 1997; 64:64.</a></li><li><a class="nounderline abstract_t">Ishiko O, Yoshida H, Sumi T, et al. Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome. Eur J Obstet Gynecol Reprod Biol 2001; 98:129.</a></li><li><a class="nounderline abstract_t">MEIGS JV. Fibroma of the ovary with ascites and hydrothorax; Meigs' syndrome. Am J Obstet Gynecol 1954; 67:962.</a></li><li><a class="nounderline abstract_t">Timmerman D, Moerman P, Vergote I. Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Gynecol Oncol 1995; 59:405.</a></li><li><a class="nounderline abstract_t">Peparini N, Chirletti P. Ovarian malignancies with cytologically negative pleural and peritoneal effusions: demons' or meigs' pseudo-syndromes? Int J Surg Pathol 2009; 17:396.</a></li><li class="breakAll">Berek JS, Hacker NF. Berek &amp; Hacker's Gynecologic Oncology, 6th edition, Wolters Kluwer, Philadelphia 2015.</li><li><a class="nounderline abstract_t">Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.</a></li><li><a class="nounderline abstract_t">Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004; 25:431.</a></li><li><a class="nounderline abstract_t">Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 2011; 35:484.</a></li><li><a class="nounderline abstract_t">Kommoss S, Gilks CB, Penzel R, et al. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology 2014; 64:380.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Female Reproductive Organs, 4th edition, Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Eds), International Agency for Research on Cancer, Lyon 2014. Vol 6.</li><li><a class="nounderline abstract_t">Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer 2003; 97:2631.</a></li><li><a class="nounderline abstract_t">Tsuji T, Catasus L, Prat J. Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors? Hum Pathol 2005; 36:792.</a></li><li><a class="nounderline abstract_t">Prat J, Scully RE. Cellular fibromas and fibrosarcomas of the ovary: a comparative clinicopathologic analysis of seventeen cases. Cancer 1981; 47:2663.</a></li><li><a class="nounderline abstract_t">Irving JA, Alkushi A, Young RH, Clement PB. Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma. Am J Surg Pathol 2006; 30:929.</a></li><li><a class="nounderline abstract_t">Cronjé HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am J Obstet Gynecol 1999; 180:323.</a></li><li><a class="nounderline abstract_t">Roth LM, Czernobilsky B. Perspectives on pure ovarian stromal neoplasms and tumor-like proliferations of the ovarian stroma. Am J Surg Pathol 2011; 35:e15.</a></li><li><a class="nounderline abstract_t">Elghorori MR, Al-Taher H, Redwood NF. Ovarian fibrothecoma: a benign neoplasm with potential adverse consequences. J Obstet Gynaecol 2003; 23:677.</a></li><li><a class="nounderline abstract_t">Liu H, Hao SH, Li WM. Giant malignant ovarian fibrothecoma involved with retroperitoneal structures mimicking a retroperitoneal sarcoma. Arch Gynecol Obstet 2009; 279:763.</a></li><li><a class="nounderline abstract_t">Nowak M, Podciechowski L, Krawczyk T, Wilczynski J. Meigs' syndrome and virilizing ovarian fibrothecoma complicating pregnancy. A case report and review of the literature. Neuro Endocrinol Lett 2009; 30:192.</a></li><li><a class="nounderline abstract_t">Staats PN, McCluggage WG, Clement PB, Young RH. Luteinized thecomas (thecomatosis) of the type typically associated with sclerosing peritonitis: a clinical, histopathologic, and immunohistochemical analysis of 27 cases. Am J Surg Pathol 2008; 32:1273.</a></li><li><a class="nounderline abstract_t">Bahar B, Hu Z, Szpaderska A, et al. Fatal case of luteinized thecoma with sclerosing peritonitis in a 40-year-old woman. Int J Gynecol Pathol 2014; 33:30.</a></li><li><a class="nounderline abstract_t">Nauen DW, Martin A, Katz A, et al. A case of luteinizing thecoma with sclerosing peritonitis: revisiting a link with anti-epileptic drugs. Pediatr Blood Cancer 2010; 54:470.</a></li><li><a class="nounderline abstract_t">Lo WK, Chan KT, Leung AC, et al. Sclerosing peritonitis complicating prolonged use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11:166.</a></li><li><a class="nounderline abstract_t">Marshall AJ, Baddeley H, Barritt DW, et al. Practolol peritonitis. A study of 16 cases and a survey of small bowel function in patients taking beta adrenergic blockers. Q J Med 1977; 46:135.</a></li><li><a class="nounderline abstract_t">Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18 Suppl 2:S81.</a></li><li class="breakAll">Young R, Clement PB, Scully RE. The ovary. In: Surgical Pathology, Sternberg SS (Ed), Raven Press, New York 1989. p.1687.</li><li><a class="nounderline abstract_t">Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360:2719.</a></li><li><a class="nounderline abstract_t">Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors: Genotype-Phenotype Correlation With Diagnostic Considerations. Int J Gynecol Pathol 2018; 37:305.</a></li><li><a class="nounderline abstract_t">Köbel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res 2009; 69:9160.</a></li><li><a class="nounderline abstract_t">Hillman RT, Lin DI, Lawson B, Gershenson DM. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol 2021; 162:728.</a></li><li><a class="nounderline abstract_t">Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol 2005; 96:204.</a></li><li><a class="nounderline abstract_t">Malmström H, Högberg T, Risberg B, Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52:50.</a></li><li><a class="nounderline abstract_t">Uygun K, Aydiner A, Saip P, et al. Granulosa cell tumor of the ovary: retrospective analysis of 45 cases. Am J Clin Oncol 2003; 26:517.</a></li><li><a class="nounderline abstract_t">Lee YK, Park NH, Kim JW, et al. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 2008; 18:642.</a></li><li><a class="nounderline abstract_t">Sehouli J, Drescher FS, Mustea A, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004; 24:1223.</a></li><li><a class="nounderline abstract_t">Evans AT 3rd, Gaffey TA, Malkasian GD Jr, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55:231.</a></li><li><a class="nounderline abstract_t">Björkholm E, Silfverswärd C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981; 11:261.</a></li><li><a class="nounderline abstract_t">Stenwig JT, Hazekamp JT, Beecham JB. Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 1979; 7:136.</a></li><li><a class="nounderline abstract_t">Auranen A, Sundström J, Ijäs J, Grénman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer 2007; 17:1011.</a></li><li><a class="nounderline abstract_t">Lauszus FF, Petersen AC, Greisen J, Jakobsen A. Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol 2001; 81:456.</a></li><li><a class="nounderline abstract_t">Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 1997; 79:1951.</a></li><li><a class="nounderline abstract_t">Crew KD, Cohen MH, Smith DH, et al. Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 2005; 96:235.</a></li><li><a class="nounderline abstract_t">Ala-Fossi SL, Mäenpää J, Aine R, et al. Prognostic significance of p53 expression in ovarian granulosa cell tumors. Gynecol Oncol 1997; 66:475.</a></li><li><a class="nounderline abstract_t">Roush GR, el-Naggar AK, Abdul-Karim FW. Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis. Gynecol Oncol 1995; 56:430.</a></li><li><a class="nounderline abstract_t">Hanley KZ, Mosunjac MB. Practical Review of Ovarian Sex Cord-Stromal Tumors. Surg Pathol Clin 2019; 12:587.</a></li><li><a class="nounderline abstract_t">Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol 2005; 29:143.</a></li><li><a class="nounderline abstract_t">Meserve EE, Nucci MR. Peutz-Jeghers Syndrome: Pathobiology, Pathologic Manifestations, and Suggestions for Recommending Genetic Testing in Pathology Reports. Surg Pathol Clin 2016; 9:243.</a></li><li><a class="nounderline abstract_t">Zung A, Shoham Z, Open M, et al. Sertoli cell tumor causing precocious puberty in a girl with Peutz-Jeghers syndrome. Gynecol Oncol 1998; 70:421.</a></li><li><a class="nounderline abstract_t">Ferry JA, Young RH, Engel G, Scully RE. Oxyphilic Sertoli cell tumor of the ovary: a report of three cases, two in patients with the Peutz-Jeghers syndrome. Int J Gynecol Pathol 1994; 13:259.</a></li><li><a class="nounderline abstract_t">Chen X, Crapanzano JP, Gonzalez AA, Hamele-Bena D. Cytologic features of needle aspiration of ovarian sex cord tumor with annular tubules: Report of two cases and literature review. Diagn Cytopathol 2018; 46:627.</a></li><li class="breakAll">Young RH. Sex cord-stromal, Sertoli cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. In: Blaustein’s Pathology of the Female Genital Tract, 6th ed, Kurman RJ, Hedrick Ellenson L, Ronnett BM (Eds), Springer, New York 2011. p.824.</li><li><a class="nounderline abstract_t">Westerman AM, Wilson JH. Peutz-Jeghers syndrome: risks of a hereditary condition. Scand J Gastroenterol Suppl 1999; 230:64.</a></li><li><a class="nounderline abstract_t">Young RH, Welch WR, Dickersin GR, Scully RE. Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982; 50:1384.</a></li><li><a class="nounderline abstract_t">Lele SM, Sawh RN, Zaharopoulos P, et al. Malignant ovarian sex cord tumor with annular tubules in a patient with Peutz-Jeghers syndrome: a case report. Mod Pathol 2000; 13:466.</a></li><li><a class="nounderline abstract_t">Rodu B, Martinez MG Jr. Peutz-Jeghers syndrome and cancer. Oral Surg Oral Med Oral Pathol 1984; 58:584.</a></li><li><a class="nounderline abstract_t">Barker D, Sharma R, McIndoe A, et al. An unusual case of sex cord tumor with annular tubules with malignant transformation in a patient with Peutz-Jeghers syndrome. Int J Gynecol Pathol 2010; 29:27.</a></li><li><a class="nounderline abstract_t">Shen K, Wu PC, Lang JH, et al. Ovarian sex cord tumor with annular tubules: a report of six cases. Gynecol Oncol 1993; 48:180.</a></li><li><a class="nounderline abstract_t">Hart WR, Kumar N, Crissman JD. Ovarian neoplasms resembling sex cord tumors with annular tubules. Cancer 1980; 45:2352.</a></li><li><a class="nounderline abstract_t">Ahn GH, Chi JG, Lee SK. Ovarian sex cord tumor with annular tubules. Cancer 1986; 57:1066.</a></li><li><a class="nounderline abstract_t">Mooney EE, Nogales FF, Tavassoli FA. Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: distinguishing a heterologous element from Leydig cells. Hum Pathol 1999; 30:611.</a></li><li><a class="nounderline abstract_t">Lim D, Oliva E. Ovarian sex cord-stromal tumours: an update in recent molecular advances. Pathology 2018; 50:178.</a></li><li><a class="nounderline abstract_t">Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012; 366:234.</a></li><li><a class="nounderline abstract_t">Schultz KA, Pacheco MC, Yang J, et al. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol 2011; 122:246.</a></li><li><a class="nounderline abstract_t">Mirshahi UL, Kim J, Best AF, et al. A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and Phenotype. JAMA Netw Open 2021; 4:e210112.</a></li><li><a class="nounderline abstract_t">Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.</a></li><li><a class="nounderline abstract_t">Martin-Jimenez A, Condom-Munró E, Valls-Porcel M, et al. [Gynandroblastoma of the ovary. Review of the literature]. J Gynecol Obstet Biol Reprod (Paris) 1994; 23:391.</a></li><li><a class="nounderline abstract_t">Fukunaga M, Endo Y, Ushigome S. Gynandroblastoma of the ovary: a case report with an immunohistochemical and ultrastructural study. Virchows Arch 1997; 430:77.</a></li></ol></div><div id="topicVersionRevision">Topic 16833 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20586551" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical, ultrasonographic, computed tomography and histopathological manifestations of ovarian steroid cell tumour, not otherwise specified: our experience of a rare case with female virilisation and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21061806" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Granulosa cell tumor and endometrial cancer: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863154" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ovarian cancer incidence in the United States, 1992-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19162310" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537089" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21481441" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Patterns of spread and recurrence of sex cord-stromal tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32336755" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664811" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The epidemiology of ovarian granulosa cell tumors: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9821198" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sex cord-stromal and steroid cell tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17433421" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Demons syndrome revisited: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995549" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serum inhibin and disease status in women with ovarian granulosa cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11516814" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13148256" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fibroma of the ovary with ascites and hydrothorax; Meigs' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8522265" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448068" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ovarian malignancies with cytologically negative pleural and peritoneal effusions: demons' or meigs' pseudo-syndromes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448068" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ovarian malignancies with cytologically negative pleural and peritoneal effusions: demons' or meigs' pseudo-syndromes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637488" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Granulosa cell tumor of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15285297" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical review of 63 cases of sex cord stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378549" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192202" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192202" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12733128" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathology and classification of ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084949" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7260859" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cellular fibromas and fibrosarcomas of the ovary: a comparative clinicopathologic analysis of seventeen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988794" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317704" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Perspectives on pure ovarian stromal neoplasms and tumor-like proliferations of the ovarian stroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617484" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ovarian fibrothecoma: a benign neoplasm with potential adverse consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18813938" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Giant malignant ovarian fibrothecoma involved with retroperitoneal structures mimicking a retroperitoneal sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675518" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Meigs' syndrome and virilizing ovarian fibrothecoma complicating pregnancy. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636018" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Luteinized thecomas (thecomatosis) of the type typically associated with sclerosing peritonitis: a clinical, histopathologic, and immunohistochemical analysis of 27 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300532" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fatal case of luteinized thecoma with sclerosing peritonitis in a 40-year-old woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847882" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A case of luteinizing thecoma with sclerosing peritonitis: revisiting a link with anti-epileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854876" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sclerosing peritonitis complicating prolonged use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/866567" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Practolol peritonitis. A study of 16 cases and a survey of small bowel function in patients taking beta adrenergic blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502809" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502809" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19516027" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mutation of FOXL2 in granulosa-cell tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700438" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors: Genotype-Phenotype Correlation With Diagnostic Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996294" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adult-type granulosa cell tumors and FOXL2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34238613" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589602" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8307501" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Granulosa cell tumors of the ovary: prognostic factors and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14528083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868338" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Characteristics of recurrence in adult-type granulosa cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154651" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6243409" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinicopathologic review of 118 granulosa and 82 theca cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7250754" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prognostic factors in granulosa-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/437566" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17374124" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371138" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149022" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prognostic factors in adult granulosa cell tumor of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589608" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299263" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic significance of p53 expression in ovarian granulosa cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705680" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097116" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Practical Review of Ovarian Sex Cord-Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644771" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27241107" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Peutz-Jeghers Syndrome: Pathobiology, Pathologic Manifestations, and Suggestions for Recommending Genetic Testing in Pathology Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790799" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sertoli cell tumor causing precocious puberty in a girl with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7523322" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oxyphilic Sertoli cell tumor of the ovary: a report of three cases, two in patients with the Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29464881" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cytologic features of needle aspiration of ovarian sex cord tumor with annular tubules: Report of two cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29464881" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cytologic features of needle aspiration of ovarian sex cord tumor with annular tubules: Report of two cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499464" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Peutz-Jeghers syndrome: risks of a hereditary condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104978" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10786816" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Malignant ovarian sex cord tumor with annular tubules in a patient with Peutz-Jeghers syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6595620" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Peutz-Jeghers syndrome and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952941" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : An unusual case of sex cord tumor with annular tubules with malignant transformation in a patient with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428688" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ovarian sex cord tumor with annular tubules: a report of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379031" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ovarian neoplasms resembling sex cord tumors with annular tubules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2417688" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ovarian sex cord tumor with annular tubules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10374766" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: distinguishing a heterologous element from Leydig cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275930" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ovarian sex cord-stromal tumours: an update in recent molecular advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187960" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501861" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630087" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3911780" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8051366" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : [Gynandroblastoma of the ovary. Review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037319" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Gynandroblastoma of the ovary: a case report with an immunohistochemical and ultrastructural study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
